Prøve GULL - Gratis

Bio Spectrum - December 2021

Gå ubegrenset med Magzter GOLD

Lese Bio Spectrum sammen med 9000+ andre magasiner og aviser med bare ett abonnement

Se katalog

1 måned

$14.99

1 år $149.99

$149.99

$12/month

(OR)

Abonner kun på Bio Spectrum

Gave Bio Spectrum

Avbryt når som helst.

(Ingen forpliktelser) ⓘ

Hvis du ikke er fornøyd med abonnementet, kan du sende oss en e-post på help@magzter.com innen 7 dager etter abonnementets startdato for full refusjon. Ingen spørsmål - lover! (Merk: Gjelder ikke for enkeltutgavekjøp)

Digitalt abonnement

Øyeblikkelig tilgang ⓘ

Abonner nå for å begynne å lese umiddelbart på Magzter-nettstedet, iOS, Android og Amazon-appene.

Verifisert sikker

betaling ⓘ

Magzter er en verifisert Authorize.Net-forhandler. Les mer

I dette nummeret

Why’s BioPharma BREAKING R&D SHACKLES?
The Indian industry bore witness to biotech companies collaborating with vaccine manufacturers, vaccine technologies being transferred, licenses to manufacture several drugs granted to pharma companies, among other notable developments. These collaborations and partnerships have furthered R&D, commercialisation and distribution of several critical drugs throughout 2021. However, key barriers to R&D-based innovation still persist in the Indian pharma market that needs to be sorted out soon. We shall take a closer look at the industry’ quest to realise even more, swift innovations and fewer hindrances.

Bio Spectrum Description:

Forlegger: MM-Activ-Sci-Tech-Communication

Kategori: Business

Språk: English

Hyppighet: Monthly

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.